Epsilon Healthcare Ltd - Asset Resilience Ratio
Epsilon Healthcare Ltd (EPN) has an Asset Resilience Ratio of 1.69% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Epsilon Healthcare Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2019)
This chart shows how Epsilon Healthcare Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Epsilon Healthcare Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Epsilon Healthcare Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EPN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$301.46K | 1.69% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$301.46K | 1.69% |
Asset Resilience Insights
- Limited Liquidity: Epsilon Healthcare Ltd maintains only 1.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Epsilon Healthcare Ltd Industry Peers by Asset Resilience Ratio
Compare Epsilon Healthcare Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Epsilon Healthcare Ltd (2016–2019)
The table below shows the annual Asset Resilience Ratio data for Epsilon Healthcare Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 12.77% | AU$3.55 Million ≈ $2.51 Million |
AU$27.81 Million ≈ $19.68 Million |
-6.57pp |
| 2018-12-31 | 19.34% | AU$6.33 Million ≈ $4.48 Million |
AU$32.75 Million ≈ $23.17 Million |
-30.95pp |
| 2017-12-31 | 50.29% | AU$11.04 Million ≈ $7.81 Million |
AU$21.95 Million ≈ $15.53 Million |
+42.57pp |
| 2016-12-31 | 7.73% | AU$885.37K ≈ $626.46K |
AU$11.46 Million ≈ $8.11 Million |
-- |
About Epsilon Healthcare Ltd
Epsilon Healthcare Limited, together with its subsidiaries, engages in the healthcare business in Australia. The company operates in three segments, Contract Development and Manufacturing Activities, Telehealth Medical Practice Services, and Pharmacy Services. It is involved in the healthcare and clinics operation; pharmaceutical contract development and manufacturing; development and manufacturi… Read more